Literature DB >> 12695732

Treatment of acute psychosis without neuroleptics: two-year outcomes from the Soteria project.

John R Bola1, Loren R Mosher.   

Abstract

The Soteria project (1971-1983) compared residential treatment in the community and minimal use of antipsychotic medication with "usual" hospital treatment for patients with early episode schizophrenia spectrum psychosis. Newly diagnosed DSM-II schizophrenia subjects were assigned consecutively (1971 to 1976, N = 79) or randomly (1976 to 1979, N = 100) to the hospital or Soteria and followed for 2 years. Admission diagnoses were subsequently converted to DSM-IV schizophrenia and schizophreniform disorder. Multivariate analyses evaluated hypotheses of equal or better outcomes in Soteria on eight individual outcome measures and a composite outcome scale in three ways: for endpoint subjects (N = 160), for completing subjects (N = 129), and for completing subjects corrected for differential attrition (N = 129). Endpoint subjects exhibited small to medium effect size trends favoring experimental treatment. Completing subjects had significantly better composite outcomes of a medium effect size at Soteria (+.47 SD, p =.03). Completing subjects with schizophrenia exhibited a large effect size benefit with Soteria treatment (+.81 SD, p =.02), particularly in domains of psychopathology, work, and social functioning. Soteria treatment resulted in better 2-year outcomes for patients with newly diagnosed schizophrenia spectrum psychoses, particularly for completing subjects and for those with schizophrenia. In addition, only 58% of Soteria subjects received antipsychotic medications during the follow-up period, and only 19% were continuously maintained on antipsychotic medications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12695732     DOI: 10.1097/01.NMD.0000061148.84257.F9

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  19 in total

Review 1.  Intensive case management for severe mental illness.

Authors:  Marina Dieterich; Claire B Irving; Bert Park; Max Marshall
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  Soteria Berne: an innovative milieu therapeutic approach to acute schizophrenia based on the concept of affect-logic.

Authors:  Luc Ciompi; Holger Hoffmann
Journal:  World Psychiatry       Date:  2004-10       Impact factor: 49.548

3.  Reassessing treatment environments after two decades: client and staff perceptions of an Italian community mental health service environment, then and now.

Authors:  Lorenzo Burti; Nicola Andreone; Mariangela Mazzi
Journal:  Community Ment Health J       Date:  2004-06

Review 4.  Crisis intervention for people with severe mental illnesses.

Authors:  Suzanne Murphy; Claire B Irving; Clive E Adams; Ron Driver
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 5.  The residential care alternative for the acutely psychotic patient.

Authors:  Pesach Lichtenberg
Journal:  Psychiatr Q       Date:  2011-12

Review 6.  Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis.

Authors:  Mario Alvarez-Jiménez; Alexandra G Parker; Sarah E Hetrick; Patrick D McGorry; John F Gleeson
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

7.  Community alternatives to inpatient admissions in psychiatry.

Authors:  Brynmor Lloyd-Evans; Sonia Johnson
Journal:  World Psychiatry       Date:  2019-02       Impact factor: 49.548

Review 8.  Antipsychotic medication for early episode schizophrenia.

Authors:  John Bola; Dennis Kao; Haluk Soydan
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 9.  A systematic review of the Soteria paradigm for the treatment of people diagnosed with schizophrenia.

Authors:  Tim Calton; Michael Ferriter; Nick Huband; Helen Spandler
Journal:  Schizophr Bull       Date:  2007-06-14       Impact factor: 9.306

Review 10.  The key role of emotions in the schizophrenia puzzle.

Authors:  Luc Ciompi
Journal:  Schizophr Bull       Date:  2014-12-06       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.